Research programme: diabetes therapy - STIL BioTechnologiesAlternative Names: SB 25; SB 29
Latest Information Update: 26 Jan 2007
At a glance
- Originator STIL BioTechnologies
- Class Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 11 Jul 2003 Preclinical trials in Diabetes mellitus in Israel (unspecified route)